Skip to main content
Premium Trial:

Request an Annual Quote

New Rules: Oct 1, 2009

The industry trade group PhRMA has new clinical trial guidelines that take effect today, reports the Wall Street Journal Health Blog. The new rules discourage ghostwriting — "authors should identify individuals who provide writing or other assistance and disclose the funding source for this assistance" — and says that doctors who have a financial stake in a drug should not be involved in a clinical trial of that drug. The guidelines also say that drug companies should post summaries of clinical trial results. However, as the Health Blog says, there is a "big grain of salt" — all the guidelines are voluntary.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.